9-1-2013

We came, we saw, we cannulated?

Hitoshi Hirose, MD, PhD
Thomas Jefferson University, Hitoshi.Hirose@Jefferson.edu

Kumar Gaurav, MD
Thomas Jefferson University, Kumar.Gaurav@jefferson.edu

Nicholas C. Cavarocchi, MD
Thomas Jefferson University, nicholas.cavarocchi@jefferson.edu

Vanjul Agarwal, MD
Thomas Jefferson University, Vanjul.Agarwal@jefferson.edu

Roselle Almeida, MD
Thomas Jefferson University, Roselle.Almeida@jefferson.edu

See next page for additional authors

Recommended Citation

Gaurav K, Cavarocchi N, Hirose H, Vaid U, Awsare B, Agarwal V, Almeida R, Toscano AJ, Baram M. We came, we saw, we cannulated? Presented at American Thoracic Society International Conference 2013. Philadelphia, PA, May 17-22, 2013.

Authors
Hitoshi Hirose, MD, PhD; Kumar Gaurav, MD; Nicholas C. Cavarocchi, MD; Vanjul Agarwal, MD; Roselle Almeida, MD; Andrew Toscano, MD; Urvashi Vaid, MD, MS; Bharat K. Awsare, M.D., FCCP; and Michael Baram, MD

We Came. We Saw. We Cannulated!

Kumar Gaurav MD[1], Nicholas Cavarocchi MD [2], Hitoshi Hirose MD , PhD [2], Vanjul Agarwal MD[1], Roselle Almeida MD[1], Andrew Toscano MD[1], Urvashi Vaid MD[1], Bharat Awsare MD[1], Michael Baram MD[1]

Division of Pulmonary & Critical Care Medicine[1] and Division of Cardiothoracic Surgery[2] , Thomas Jefferson University Philadelphia PA

INTRODUCTION

•In patients with refractory gas-exchange abnormalities, extracorporeal membrane oxygenation (ECMO) is considered rescue therapy that aims to decrease ventilator induced lung injury and provide lung rest.

AIM

• To compare the cohort of patients who received ECMO as rescue therapy compared to other forms of rescue therapy at our institution.

METHODS

- We conducted a retrospective study of patients diagnosed with ARDS (N=149) from October 2010 to September 2012 at Thomas Jefferson Hospital.
- All patients mechanically ventilated with on the ARDS protocol were identified. Severity of illness and lung injury were determined based on APACHE II, PaO2 / FiO2 ratio, Oxygenation Index (OI) and Murray score.
- Subjects who required additional therapy became the cohort known as rescue therapy. These patients required the use of- inhaled Epoprostenol, neuromuscular blocking agents and /or Airway pressure release ventilation (APRV) to identified.

RESULTS

•149 patients were identified, 62 patients received rescue therapy and 14 required ECMO.

•Six of 14 patients received Veno-arterial ECMO and the remaining 8 received Veno-venous ECMO.

•Patients with ARDS placed on ECMO had an absolute reduction in mortality of 27% when compared to patients who received other rescue modalities (77% vs. 50%; p = 0.32).

Initial patient characteristics in different treatment groups

Parameters	No rescue therapy	Non ECMO rescue modality	ECMO rescue modality	CESAR Trial
Demographics				
Total patients n=149	87 (59%)	48 (32%)	14 (9%)	90
Age (years)	56 (30-86)	53 (22-91)	47 (17-77)	40
Etiology				
Pneumonia	49%	50%	50%	62%
Sepsis	34%	30%	21%	
Initial Oxygenation				
FiO_2	60 (30-100)	70 (40-100)	100 (70-100)	
Murray Score	2 (1-4)	3 (1.75-4)	3.5 (2.5-4)	3.5
Oxygenation Index	7 (2-23)	15 (3- 41)	26 (11-59)	
PaO_2/FiO_2	94 (60-490)	116 (53-383)	75 (41-144)	76
Initial Lung Mechanics				
Static compliance	30 (17-230)	26 (11-75)	24 (10-60)	28
MAP cmH_2O	9 (7-26)	18.5 (13-30)	21 (26-70)	
PEEP cmH_2O	8 (5-14)	10 (5-20)	15 (5-20)	14
pH	7.40 (7.2-7.5)	7.34 (7.13-7.5)	7.30 (6.96-7.5)	7.10
pCO_2 mmHg	41 30-68)	40 (26-76)	45 (41-144)	
pO_2 mmHg	92 (61-194)	81(48-383)	69 (25-116)	
APACHE II Score	23 (7-42)	24 (8-43)	29 (11-39)	20
Mortality rate	**39%**	**77%**	**50%**	**37%**

Data are number (%) or median (range)

A-a gradient: alveolar arterial gradient; **MAP:** Mean airway pressure, **Oxygenation Index** = FiO_2 x MAP/ PaO_2

Different rescue modalities used in Non ECMO rescue group



DISCUSSION

- Patients with severe ARDS have a high mortality rate and often receive rescue therapy for gas exchange abnormalities.
- There is growing appreciation that ECMO therapy is a valuable rescue therapy but there is controversy about selection of the right candidate.
- There was a trend towards improved survival in the ECMO group.
- Severe hypoxemia coupled with elevated PaCO2 and younger age appeared to be triggers for use of ECMO at our institution.
- These data provide support for using ECMO as rescue therapy in select populations. Hopefully future research will identify parameters to identify patients early who will benefit from ECMO therapy.
- Our outcomes are similar to Cesar trial.

CONCLUSION

- We believe that ECMO may be an important rescue modality in the right clinical setting in patients with severe ARDS.
- Treating physicians should consider ECMO as a treatment modality for severe ARDS patients.